Core Points - The National Healthcare Security Administration (NHSA) has released a draft plan for the adjustment of the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug Catalogs, as well as the Commercial Health Insurance Innovative Drug Catalog, marking the upcoming negotiations for 2025 [1][3] - This year, the introduction of the Commercial Health Insurance Innovative Drug Catalog allows companies to choose between two options for innovative drug development, which is expected to significantly promote innovation [1][3] - The adjustment process will be more stringent due to ongoing financial constraints in the healthcare system, focusing support on truly innovative products while being less favorable to Me-too products [2][3] Drug Catalog Adjustment - Since the establishment of the NHSA in 2018, the adjustment cycle for the drug catalog has been shortened from a maximum of 8 years to 1 year, with a focus on new drugs launched within the last 5 years [3] - The 2025 adjustment will continue to focus on new drugs approved between January 1, 2020, and June 30, 2025, with an emphasis on clinical necessity, safety, effectiveness, and reasonable pricing [3][4] - The criteria for inclusion in the regular catalog management have been revised, removing the requirement for exclusive drugs to have not adjusted payment standards for two consecutive agreement periods [4] Commercial Health Insurance Role - The new plan emphasizes the significant decision-making power of commercial health insurance experts in the evaluation and pricing negotiation processes for the innovative drug catalog [7][8] - Experts involved in the evaluation will be recommended from various sectors, including commercial insurance companies and healthcare departments, ensuring a comprehensive assessment of the drugs [7] - The policy shift allows insurance companies to transition from passive payers to active participants in the healthcare ecosystem, enhancing their role in the drug catalog formulation process [8]
国谈在即：严控价格，伪创新药品或迎大考
2 1 Shi Ji Jing Ji Bao Dao·2025-07-02 07:52